Titanovo Logo
Back to Cell Types

SU-DHL-4Homo sapiens (Human)Cancer cell line

Also known as: SUDHL4, Sudhl4, SUDHL-4, Sudhl-4, SuDHL 4, SUD-4, SUD4, SU4, Stanford University-Diffuse Histiocytic Lymphoma-4, DHL-4, DHL4

🤖 AI SummaryBased on 8 publications

Quick Overview

SU-DHL-4 is a human B-cell lymphoma cell line used in cancer research.

Detailed Summary

SU-DHL-4 is a human B-cell lymphoma cell line derived from a patient with diffuse large B-cell lymphoma (DLBCL). It is widely used in research to study the molecular mechanisms of lymphoma, particularly focusing on genetic alterations such as the t(14;18) translocation involving the BCL-2 gene. This cell line is known for its expression of BCL-2 and has been utilized in studies examining the role of BCL-2 in lymphomagenesis and therapeutic resistance. SU-DHL-4 is also used to investigate the effects of various treatments, including chemotherapy and targeted therapies, on lymphoma cells. Its characteristics make it a valuable model for understanding the biology of DLBCL and developing new treatment strategies.

Research Applications

Study of BCL-2 gene alterations and their role in lymphomagenesisInvestigation of therapeutic resistance mechanisms in DLBCLEvaluation of targeted therapies and chemotherapeutic agentsAnalysis of genetic and molecular characteristics of lymphoma cells

Key Characteristics

Expresses BCL-2 proteinCarries t(14;18) translocation involving BCL-2Used as a model for DLBCL researchRelevant for studying therapeutic resistance
Generated on 6/15/2025

Basic Information

Database IDCVCL_0539
SpeciesHomo sapiens (Human)
Tissue SourcePeritoneal effusion[UBERON:UBERON_0001268]

Donor Information

Age38
Age CategoryAdult
SexMale

Disease Information

DiseaseDiffuse large B-cell lymphoma germinal center B-cell type
LineageLymphoid
SubtypeDiffuse Large B-Cell Lymphoma, NOS
OncoTree CodeDLBCLNOS

DepMap Information

Source TypeDSMZ
Source IDACH-000365_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
Gene fusionBCL2IGH-BCL2--from parent cell line SU-DHL-4
MutationSimpleEZH2p.Tyr646Ser (c.1937A>C) (Y641S)Heterozygous-from parent cell line SU-DHL-4
MutationSimpleEZH2p.Tyr666Asn (c.1996T>A) (Y661N)Heterozygous-from parent cell line SU-DHL-4
MutationSimpleTP53p.Arg273Cys (c.817C>T)Homozygous-PubMed=35933914

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
12
D13S317
11,12
D16S539
11,13
D18S51
14,16
D19S433
14
D21S11
29,30
D2S1338
17,19
D3S1358
15,16
D5S818
11,12
D7S820
8,11
D8S1179
13
FGA
19,21
Penta D
9,14
Penta E
7,11
TH01
6,9.3
TPOX
9,11
vWA
18,19
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.

Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.

Leuk. Lymphoma 57:1015-1020(2016).

DOIPubMed

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOIPubMedPMC

The LL-100 panel: 100 cell lines for blood cancer studies.";

MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.

Sci. Rep. 9:8218-8218(2019).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

DOIPubMedPMC

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

DOIPubMedPMC

Smoothened stabilizes and protects TRAF6 from degradation: a novel non-canonical role of smoothened with implications in lymphoma biology.

Lossos I.S., Landgraf R., Vega-Vazquez F.

Cancer Lett. 436:149-158(2018).

DOIPubMed

Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.

Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.

Clin. Cancer Res. 24:3967-3980(2018).

DOIPubMed

Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.

Pham L.V.

Oncotarget 9:346-360(2018).

DOIPubMedPMC

Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.

Kadin M.E., Del Mistro A., Woessner R.D., Jaffe E.S., Waldmann T.A.

Proc. Natl. Acad. Sci. U.S.A. 114:3975-3980(2017).

DOIPubMedPMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

DOI

Identification of cell lines with variable numbers of tandem repeat (VNTR) amplified by polymerase chain reaction.

Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.

Tissue Cult. Res. Commun. 15:211-219(1996).

DOI

Biology and virology of the human malignant lymphomas: 1st Milford D. Schulz Lecture.

Kaplan H.S., Goodenow R.S., Gartner S., Bieber M.M.

Cancer 43:1-24(1979).

DOIPubMed

Biology of the human malignant lymphomas. III. Intracranial heterotransplantation in the nude, athymic mouse.

Epstein A.L., Herman M.M., Kim H., Dorfman R.F., Kaplan H.S.

Cancer 37:2158-2176(1976).

DOIPubMed

Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines.

Epstein A.L., Levy R., Kim H., Henle W., Henle G.S., Kaplan H.S.

Cancer 42:2379-2391(1978).

DOIPubMed

Feeder layer and nutritional requirements for the establishment and cloning of human malignant lymphoma cell lines.

Epstein A.L., Kaplan H.S.

Cancer Res. 39:1748-1759(1979).

PubMed

Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation.

Cleary M.L., Smith S.D., Sklar J.

Cell 47:19-28(1986).

DOIPubMed

Isoenzyme studies in human leukemia-lymphoma cell lines -- 1. carboxylic esterase.

Drexler H.G., Gaedicke G., Minowada J.

Leuk. Res. 9:209-229(1985).

DOIPubMed

Isoenzyme studies in human leukemia-lymphoma cell lines -- III. Beta-hexosaminidase (E.C. 3.2.1.30).

Drexler H.G., Gaedicke G., Minowada J.

Leuk. Res. 9:549-559(1985).

DOIPubMed

Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.

Drexler H.G., Gaedicke G., Minowada J.

Leuk. Res. 9:537-548(1985).

DOIPubMed

Histiocytic lymphoma cell lines: immunologic and cytogenetic studies.

Hecht F.

Cancer Genet. Cytogenet. 14:205-218(1985).

DOIPubMed

Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.

Uppenkamp M.J., Nowrousian M.R., Seeber S., Opalka B.

Br. J. Haematol. 91:350-354(1995).

DOIPubMed

Metastatic potential of lymphoma/leukemia cell lines in SCID mice is closely related to expression of CD44.

Liu C., Kondo E., Minowada J., Akagi T.

Jpn. J. Cancer Res. 87:1070-1077(1996).

DOIPubMedPMC

Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.

Aizawa Y., Ueda R., Seto M.

Jpn. J. Cancer Res. 89:712-718(1998).

DOIPubMedPMC

PTEN gene alterations in lymphoid neoplasms.";

Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.

Blood 92:3410-3415(1998).

DOIPubMed

Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Leuk. Res. 24:255-262(2000).

DOIPubMed

Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262.

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Leuk. Res. 25:275-278(2001).

DOIPubMed

Microarray analysis of B-cell lymphoma cell lines with the t(14;18).

Elenitoba-Johnson K.S.J.

J. Mol. Diagn. 4:123-136(2002).

DOIPubMedPMC

The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

Schenkein D., Lister T.A., Joel S.P.

Cancer Res. 67:2783-2790(2007).

DOIPubMed

Generation of multidrug resistant lymphoma cell lines stably expressing P-glycoprotein.

Pop I., Pop L., Vitetta E.S., Ghetie M.-A.

Oncol. Rep. 19:889-895(2008).

DOIPubMed

Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.

Robetorye R.S., Aguiar R.C.T.

Blood 113:6681-6690(2009).

DOIPubMedPMC

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Cook J.R., Weisenburger D.D., Chan W.-C., Pierce S.K., Staudt L.M.

Nature 463:88-92(2010).

DOIPubMedPMC

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Kutok J.L., Shipp M.A.

Blood 116:3268-3277(2010).

DOIPubMedPMC

Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-kappaB-inducing kinase while activating both canonical and alternative nuclear factor-kappaB pathways.

Vega-Vazquez F., Medeiros L.J., Ford R.J. Jr.

Blood 117:200-210(2011).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Genetic heterogeneity of diffuse large B-cell lymphoma.";

Dunson D.B., Dave S.S.

Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).

DOIPubMedPMC

High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.

O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.

J. Virol. 89:713-729(2015).

DOIPubMedPMC

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A mass spectrometric-derived cell surface protein atlas.";

Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.

PLoS ONE 10:E0121314-E0121314(2015).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

Web Resources

tcpaportal.org